Improved Prediction of Breast Cancer Prognosis with p53 and PSA
Author Information
Author(s): Yu H, Levesque M A, Clark G M, Diamandis E P
Primary Institution: Feist-Weiller Cancer Center, Louisiana State University Medical Center
Hypothesis
Assessing p53 and prostate-specific antigen (PSA) together can improve breast cancer prognosis prediction.
Conclusion
Combining the assessment of p53 and PSA can better stratify breast cancer patients by their risks of relapse and death compared to evaluating each marker alone.
Supporting Evidence
- p53 gene mutation is common in breast cancer and may indicate poor prognosis.
- PSA expression may help identify breast cancer patients with a favorable outcome.
- The study found that PSA-negative and p53-positive patients had significantly higher risks for relapse and death.
Takeaway
Doctors can better predict how breast cancer will affect patients by looking at two markers, p53 and PSA, together instead of just one.
Methodology
The study used quantitative enzyme-linked immunosorbent assays (ELISAs) to assess p53 and PSA in breast cancer samples and analyzed the data using Cox regression and Kaplan–Meier methods.
Statistical Information
P-Value
0.020 for DFS, 0.023 for OS
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website